Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer.
暂无分享,去创建一个
Michael Baumann | Rosalind Perrin | Daniel Zips | Jörg Kotzerke | Jörg Steinbach | Nasreddin Abolmaali | Klaus Zöphel | Robert Haase | Andrij Abramyuk | J. Steinbach | M. Baumann | D. Zips | N. Abolmaali | J. Kotzerke | K. Zöphel | R. Perrin | A. Abramyuk | R. Haase | S. Appold | Steffen Appold
[1] C. Ling,et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. , 2009, International journal of radiation oncology, biology, physics.
[2] Richard Laforest,et al. Assessing Tumor Hypoxia in Cervical Cancer by PET with 60Cu-Labeled Diacetyl-Bis(N4-Methylthiosemicarbazone) , 2008, Journal of Nuclear Medicine.
[3] Lei Dong,et al. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. , 2012, International journal of radiation oncology, biology, physics.
[4] M. Schwaiger,et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. , 2007, International journal of radiation oncology, biology, physics.
[5] T K Lewellen,et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. , 1996, International journal of radiation oncology, biology, physics.
[6] H. Feldmann,et al. Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] Liane Oehme,et al. Automatische Volumenabgrenzung in der onkologischen PET – Bewertung eines entsprechenden Software-Werkzeugs und Vergleich mit manueller Abgrenzung anhand klinischer Datensätze , 2012 .
[8] David L. Schwartz,et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer , 2006, Clinical Cancer Research.
[9] Ming-fang Wang,et al. Fully automated one-pot synthesis of [18F]fluoromisonidazole. , 2005, Nuclear medicine and biology.
[10] M. Baumann,et al. Prognostic Value of Radiobiological Hypoxia during Fractionated Irradiation for Local Tumor Control , 2011, Strahlentherapie und Onkologie.
[11] Radhe Mohan,et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. , 2004, International journal of radiation oncology, biology, physics.
[12] Daniela Thorwarth,et al. Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer , 2005, BMC Cancer.
[13] Johannes H Kaanders,et al. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] J. Overgaard. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck--a systematic review and meta-analysis. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[15] Sigrid Stroobants,et al. Dose Painting in Radiotherapy for Head and Neck Squamous Cell Carcinoma: Value of Repeated Functional Imaging with 18F-FDG PET, 18F-Fluoromisonidazole PET, Diffusion-Weighted MRI, and Dynamic Contrast-Enhanced MRI , 2009, Journal of Nuclear Medicine.
[16] R. Fisher,et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Krause,et al. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[18] S. Welz,et al. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[19] J. Kaanders,et al. ARCON: experience in 215 patients with advanced head-and-neck cancer. , 2001, International journal of radiation oncology, biology, physics.
[20] J. Petersen,et al. Imaging hypoxia to improve radiotherapy outcome , 2012, Nature Reviews Clinical Oncology.
[21] Matthias Reimold,et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] J. Steinbach,et al. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best? , 2010, Nuklearmedizin. Nuclear medicine.
[23] L. Bastholt,et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] Daniela Thorwarth,et al. Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps , 2011, Physics in medicine and biology.
[25] Kevin Harrington,et al. An exploratory study into the role of dynamic contrast-enhanced magnetic resonance imaging or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer. , 2009, International journal of radiation oncology, biology, physics.
[26] Michael C. Joiner,et al. Basic Clinical Radiobiology , 2009 .
[27] Roland Bares,et al. Hypoxia-imaging with 18F-Misonidazole and PET: Changes of kinetics during radiotherapy of head-and-neck cancer , 2007 .
[28] M. Baumann,et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] M. Baumann,et al. Zwei oder vier Stunden [18F]FMISO-PET in Kopf-Hals-Karzinomen: , 2011 .
[30] B. Beuthien-Baumann,et al. Radiobiological hypoxia, oxygen tension, interstitial fluid pressure and relative viable tumour area in two human squamous cell carcinomas in nude mice during fractionated radiotherapy. , 2001 .
[31] J. Lee,et al. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[32] S. Roberts,et al. Changes in oxygenation during radiotherapy in carcinoma of the cervix. , 1999, International Journal of Radiation Oncology, Biology, Physics.
[33] Marianne Patt,et al. [18F]Fluoroazomycinarabinofuranoside (18FAZA) and [18F]Fluoromisonidazole (18FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. , 2003, Nuclear medicine and biology.
[34] J. Overgaard,et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.
[35] Tomio Inoue,et al. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study , 2011, Annals of nuclear medicine.
[36] B. S. Sørensen,et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] P. Wust,et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] F Hofheinz,et al. Automatic volume delineation in oncological PET , 2011, Nuklearmedizin.
[39] M. Senda,et al. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma , 2011, Annals of nuclear medicine.
[40] Georgy Shakirin,et al. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors , 2010, Acta radiologica.